A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Advanced Melanoma
Interventions
DRUG

Botensilimab

An anti-CTLA-4 monoclonal antibody

DRUG

Balstilimab

An anti-PD-1 monoclonal antibody

Trial Locations (51)

1011

CHUV - Centre hospitalier universitaire vaudois, Lausanne

1090

Universitair Ziekenhuis Brussel, Jette

8035

Hospital Universitario Vall d'Hebron, Barcelona

8036

Hospital Clinic Barcelona, Barcelona

20014

Onkologikoa, Donostia / San Sebastian

20057

Georgetown University Medical Center, Washington D.C.

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

24105

University Hospital Schleswig-Holstein, Kiel

28007

Hospital General Universitario Gregorio Maranon, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

35042

Centre Eugene Marquis, Rennes

38700

CHU Grenoble-Alpes - Hopital Michallon, La Tronche

41009

Hospital Universitario Virgen Macarena, Seville

44093

CHU de Nantes, Nantes

45122

Universitaetsklinikum Essen, Essen

46014

Consorcio Hospital General Universitario de Valencia, Valencia

47014

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l., Meldola

53100

Azienda Ospedaliero Universitaria Senese, Siena

55131

Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz, Mainz

69008

Centre Leon Berard, Lyon

69120

Universitaetsklinikum Heidelberg, Heidelberg

72076

Universitaetsklinikum Tuebingen, Tübingen

75010

AP-HP Hopital Saint-Louis, Paris

80054

CHU Amiens Picardie - Hopital Sud, Amiens

80131

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli

80377

Klinikum der Universitaet München, München

85258

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale

90404

Providence Saint John's Health Center, Santa Monica

92835

Virginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton

97080

Universitaetsklinikum Würzburg, Würzburg

115478

Blokhin National Medical Research Oncology Centre, Moscow

121205

"Branch Office of Hadassah Medical Ltd", Moscow

143423

Moscow City Oncology Hospital #62, Moscow

194356

LLC Medical Services, Saint Petersburg

195271

Clinical Hospital Russian Railways - Medicine, Saint Petersburg

197758

Petrov National Medical Research Center of Oncology, Saint Petersburg

06520-8028

Yale University School of Medicine - Yale Cancer Center, New Haven

02215

Dana-Farber Cancer Institute, Boston

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

98700-000

Oncosite - Centro de Pesquisa Clinica Em Oncologia, Ijuí

17210-080

Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho, Jaú

90110-270

Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa, Porto Alegre

20220-410

INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva, Rio de Janeiro

01308-050

Hospital Sirio Libanes, São Paulo

01323-001

Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo, São Paulo

01509-010

Hospital A.C. Camargo Cancer Center, São Paulo

Unknown

Gustave Roussy, Villejuif

CH-8091

Universitaetsspital Zuerich, Zurich

SW3 6JJ

Royal Marsden Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

HA6 2RN

Mount Vernon Cancer Centre, Middlesex

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Agenus Inc.

INDUSTRY

NCT05529316 - A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Biotech Hunter | Biotech Hunter